Valence Life Sciences

CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders. CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006.

CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders. CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006.

JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treat patients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities. JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques. Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California.

Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques. Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California.

Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques. Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California.

Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques. Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California.